Halocarbon Products Corporation

Barry Malcolm Jones

Joel Swinson

Paul Mazzell, Jr

Neville Pavri

Ashot Khrimian

Danny Graham

Paul Cross

Achot Pavlikovich Khrimian

Paul Mazzell

Daniel Graham

A process for preparing fluorinated ethers, such as desflurane, comprises reacting the corresponding chlorinated ether, such as isoflurane, with anhydrous hydrogen fluoride in the vapor phase in the presence of chromia catalyst. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Synthesis of fluorinated ethers

Processes for preparing commercial quantities of a stable, pharmaceutically acceptable sevoflurane substantially free of impurities are claimed. In another embodiment, a process for removing reactive metal salts from the surface of metallic equipment used in the distillation of sevoflurane and rendering a non-inert metallic surface of the metallic equipment inert.

Distillation method for the purification of sevoflurane and the maintenance of certain equipment that may be used in the distillation process

An azeotrope comprising desflurane (CFCFHOCFH) and hydrogen fluoride (HF). The azeotrope can be prepared by fractionally distilling a crude mixture of desflurane and HF. Purer desflurane can be readily and easily separated from the azeotrope. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Separation/purification of desflurane from hydrogen fluoride

Crude sevoflurane product comprising unacceptably high levels of HFIP can be purified by combining the crude sevoflurane product with sufficient water to produce a multiphase mixture, fractionally distilling the multiphase mixture, removing sevoflurane from the distilling multiphase mixture as an azeotrope with water, and separating substantially pure sevoflurane from the azeotrope.

Purification of Fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether (sevoflurane)

A process for purifying crude fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether (sevoflurane). The crude sevoflurane is repeatedly washed with water under conditions and for a time sufficient to reduce the level of 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) to no more than 200 ppm or no more than 100 ppm.

Process for the purification of fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether (sevoflurane)

1,1,1,3,3,3-Hexafluoroisopropanol (HFIP) substantially free of 1,1,1-trifluoroacetone (TFA) can be separated from a mixture containing both compounds by A) catalytic reduction with hydrogen followed by fractional distillation; B) cooling to a temperature at which HFIP freezes and TFA remains liquid; C) forming a high boiling complex comprising HF and TFA followed by fractional distillation; or D) producing HF-free conditions to yield a HFIP/TFA azeotrope followed by fractional distillation. It is emphasized that this abstract is provided to comply with the rules requiring an abstract, which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR &#xa7; 1.72(b).

Purification of 1,1,1,3,3,3-hexafluoroisopropanol

A method in which organic matter found in a crude sevoflurane may be separated, identified, and quantified using a CARBOWAX&#x2122; (polyethylene glycol) capillary gas chromatographic column or an alkyl polysiloxane capillary gas chromatographic column. Also provided is a process control method for the production of sevoflurane, wherein the content of a particular component in one of the following steps is determined, and in that, assuming this as a variable, the treatment condition of the step is adjusted: 1) a step of extracting, or cooling to form two layers, and/or distilling a mixture of crude sevoflurane and hydrogen fluoride (HF) in order to isolate the majority of the sevoflurane and 2) an optional step of purifying the crude sevoflurane and 3) a step of distilling crude sevoflurane. Also provided is a method for determining the impurity level of a purified sevoflurane that is acceptable for use in human/animal anesthesia.

Chromatographic method for the analysis of both in process and finished sevoflurane

An improved process for preparing fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether(sevoflurane) by reacting 1,1,1,3,3,3-hexafluoro-2-propanol with formaldahyde and hydrogen fluoride either A) under distillation conditions or B) in the presence of or with the subsequent addition of a solvent capable of selectively extracting sevoflurane.

Growing community of inventors

North Augusta, SC, United States of America

Barry Malcolm Jones